The collaboration includes the marketing and distribution of advanced medical cannabis products, including cannabis extracts for inhalation, produced by Panaxia. The medical cannabis market in the Czech Republic[1] The Czech Republic is one of the most advanced countries in Europe in terms of the medical cannabis market size. The medical cannabis market in Switzerland[2] Switzerland holds a leading position worldwide in the medical sector. Panaxia operates two EU-GMP facilities in Israel and Malta, which allow the export of advanced medical cannabis products to most European countries. This is expected to add thousands of additional patients to the legal, regulated medical cannabis market in the country. [1] Prohibition Partners, The European Cannabis Report, 7th edition; https://prohibitionpartners.com/2022/01/19/could-czech-republic-be-europes-most-progressive-medical-cannabis-market/
Both companies will expand their cooperation through the distribution of medical cannabis products in the highly attractive Czech and Swiss markets
Dusseldorf and Barcelona / Tel Aviv, October 6, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), and Panaxia (TASE: PNAX), a global pharmaceutical company that develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality, today announced the signing of two addendums to their agreement to expand...
Read the full article @ Cannabis Law Report